Payment overview · 2025
General Payments
$264.63
16 reported records · 5 companies
Healthcare provider profile · identity verified
Kerry Hanna, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NEWPORT, AR · NPI 1245680321
Verified facts
What the public records show
CMS Open Payments records show Kerry Hanna, APRN received $264.63 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 57.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.34 | 57.6% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.77 | 24.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.05 | 6.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.59 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.88 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.63 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.34 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.77 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 65 |
| Lisinopril | Lisinopril | 122 | 42 |
| Omeprazole | Omeprazole | 106 | 35 |
| Metformin Hcl | Metformin Hcl | 90 | 32 |
| Mounjaro | Tirzepatide | 86 | 16 |
| Gabapentin | Gabapentin | 85 | 25 |
| Jardiance | Empagliflozin | 83 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 79 | 28 |
| Clonazepam | Clonazepam | 79 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 22 |
| Furosemide | Furosemide | 65 | 19 |
| Ozempic | Semaglutide | 64 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 25 |
| Losartan Potassium | Losartan Potassium | 52 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 16 |
| Sertraline Hcl | Sertraline Hcl | 43 | 14 |
| Azithromycin | Azithromycin | 41 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 31 |
| Meloxicam | Meloxicam | 36 | 14 |
| Prednisone | Prednisone | 36 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Potassium Chloride | Potassium Chloride | 35 | 16 |
| Famotidine | Famotidine | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 31 | 11 |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 14 |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.63 · 16 records | ABBVIE INC. | BREZTRI, Cologuard Collection Kit, JARDIANCE, TRELEGY ELLIPTA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error